Story on Restless Legs Syndrome

One implication of the NYT story on restless legs syndrome (RLS) (http://well.blogs.nytimes.com/2008/12/17/voices-of-restless-legs-syndrome/) seems, in my opinion, to be that doctors may not be as aware of the existence of RLS, as a clinical entity, as they could or perhaps should be. This may be a valid point, but I think many neurologists and most medical doctors who specialize in the treatment of sleep disorders would be aware of a lot of the research on and atypical manifestations of the condition. I guess the article communicates that. A lot of the research suggests that RLS tends to be a manifestation of very complex neurobiological changes and that these changes include inter-individual differences in gene expression, etc., in neurons in the spinal cord and not just the brainstem. It's my understanding that anything that decreases D2 dopamine receptor density, in the long-term or even in the short-term, and or patterns of D2 dopamine receptor activation (i.e. tonic vs. phasic activation, etc.) could produce the symptoms. This effect could be produced by a large range of drugs. Most of the research on the topic is in sleep-related journals.